NASDAQ:VALN Valneva (VALN) Stock Forecast, Price & News $11.36 -0.25 (-2.15%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$11.33▼$12.0750-Day Range$11.36▼$15.2952-Week Range$9.07▼$17.05Volume9,071 shsAverage Volume5,521 shsMarket Capitalization$789.07 millionP/E Ratio81.14Dividend YieldN/APrice Target$22.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Valneva MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside93.7% Upside$22.00 Price TargetShort InterestHealthy0.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.48) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector435th out of 969 stocksBiological Products, Except Diagnostic Industry65th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingValneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Valneva has a forecasted upside of 93.7% from its current price of $11.36.Amount of Analyst CoverageValneva has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.01% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently increased by 24.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VALN. Previous Next 2.9 News and Social Media Coverage News SentimentValneva has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Valneva this week, compared to 2 articles on an average week.Search Interest1 people have searched for VALN on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.98% of the stock of Valneva is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Valneva are expected to decrease in the coming year, from ($0.48) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is 81.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is 81.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 151.41.Price to Book Value per Share RatioValneva has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Valneva (NASDAQ:VALN) StockValneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Read More VALN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VALN Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Receives "Buy" Rating from Needham & Company LLCSeptember 28, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Stock Rating Reaffirmed by HC WainwrightSeptember 29, 2023 | Stansberry Research (Ad)1907, 1929, 1998, 2007--and now 2023?Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.September 27, 2023 | finance.yahoo.comValneva SE (NASDAQ:VALN) Q2 2023 Earnings Call TranscriptSeptember 25, 2023 | markets.businessinsider.comBuy Rating for Valneva: Future Prospects and Financial AnalysisSeptember 25, 2023 | msn.comValneva receives JE vaccine supply contract from US DoDSeptember 25, 2023 | msn.comValneva gets new $32M supply contract for the U.S. governmentSeptember 25, 2023 | finance.yahoo.comValneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 MillionSeptember 29, 2023 | Stansberry Research (Ad)1907, 1929, 1998, 2007--and now 2023?Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.September 21, 2023 | msn.comU.S. FDA found lapses at Novo's main U.S. factory in May 2022 -reportSeptember 21, 2023 | markets.businessinsider.comValneva Reports Half Year 2023 Financial Results and Provides Corporate UpdatesSeptember 21, 2023 | marketwatch.comValneva Loss Narrows on Reduced CostsSeptember 21, 2023 | msn.comValneva's half-year loss narrows on strong travel vaccine demandSeptember 21, 2023 | finance.yahoo.comValneva Reports Half Year 2023 Financial Results and Provides Corporate UpdatesSeptember 8, 2023 | msn.comPfizer Lyme Disease Vaccine Shows PromiseSeptember 7, 2023 | markets.businessinsider.comAnalyst Ratings for ValnevaSeptember 7, 2023 | markets.businessinsider.comValneva Reports Positive Pediatric & Adolescent Phase 2 Booster Results For Lyme Disease VaccineSeptember 6, 2023 | finance.yahoo.comVALNEVA Declaration of shares and voting rights: August 31, 2023August 31, 2023 | finance.yahoo.comValneva to Participate in Investor Conferences in the United States and Europe in September 2023August 29, 2023 | msn.comHealth Canada accepts Valneva’s chikungunya vaccine filing for reviewAugust 29, 2023 | markets.businessinsider.comCanada Accepts Valneva's Chikungunya Vaccine License Application For ReviewAugust 29, 2023 | tmcnet.comHealth Canada Accepts Valneva's Chikungunya Vaccine License Application for ReviewAugust 29, 2023 | finance.yahoo.comHealth Canada Accepts Valneva’s Chikungunya Vaccine License Application for ReviewAugust 28, 2023 | finanznachrichten.deVALNEVA: Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine CandidateAugust 28, 2023 | markets.businessinsider.comValneva Reports Positive Safety Data In Adolescents For Chikungunya Vaccine CandidateAugust 28, 2023 | marketwatch.comValneva Gets Positive Data in Chikungunya Vaccine TrialAugust 28, 2023 | msn.comValneva reports data from chikungunya vaccine trial in adolescentsSee More Headlines Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Email Address VALN Company Calendar Today9/29/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VALN CUSIPN/A CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees719Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$22.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+93.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.14 Trailing P/E Ratio81.14 Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,960,000.00 Net Margins-2.85% Pretax Margin-40.08% Return on Equity-4.86% Return on Assets-1.51% Debt Debt-to-Equity Ratio0.41 Current Ratio1.48 Quick Ratio1.33 Sales & Book Value Annual Sales$380.73 million Price / Sales2.07 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book3.39Miscellaneous Outstanding Shares69,460,000Free Float59,100,000Market Cap$789.07 million OptionableNot Optionable Beta2.69 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Thomas Lingelbach (Age 60)Chairman of the Management Board, Pres & CEO Comp: $853.43kMr. Peter Buhler (Age 52)CFO & Management Board Member Comp: $566.26kMr. Franck Grimaud MBA (Age 56)Director Gen., Chief Bus. Officer & Member of Management Board Comp: $423.93kMr. Frederic Jacotot (Age 58)VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board Comp: $325.04kDr. Juan-Carlos Jaramillo M.D. (Age 51)Chief Medical Officer & Member of the Management Board Comp: $514.58kMs. Dipal Patel (Age 49)Chief Commercial Officer & Member of Management Board Comp: $826.98kMr. Perry CelentanoInterim Chief Operating OfficerMr. Joshua Drumm Ph.D.VP of Investor RelationsMs. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsMr. Gerald StrohmaierVP of Human ResourceMore ExecutivesKey CompetitorsKymera TherapeuticsNASDAQ:KYMRImmaticsNASDAQ:IMTXInhibrxNASDAQ:INBXAdaptive BiotechnologiesNASDAQ:ADPTADMA BiologicsNASDAQ:ADMAView All Competitors VALN Stock - Frequently Asked Questions Should I buy or sell Valneva stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VALN shares. View VALN analyst ratings or view top-rated stocks. What is Valneva's stock price forecast for 2023? 2 brokerages have issued twelve-month price targets for Valneva's stock. Their VALN share price forecasts range from $22.00 to $22.00. On average, they predict the company's share price to reach $22.00 in the next year. This suggests a possible upside of 93.7% from the stock's current price. View analysts price targets for VALN or view top-rated stocks among Wall Street analysts. How have VALN shares performed in 2023? Valneva's stock was trading at $12.72 at the start of the year. Since then, VALN stock has decreased by 10.7% and is now trading at $11.3601. View the best growth stocks for 2023 here. Are investors shorting Valneva? Valneva saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,600 shares, an increase of 24.5% from the August 31st total of 5,300 shares. Based on an average trading volume of 5,100 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.0% of the shares of the company are short sold. View Valneva's Short Interest. When is Valneva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our VALN earnings forecast. What guidance has Valneva issued on next quarter's earnings? Valneva issued an update on its FY 2023 earnings guidance on Thursday, September, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $239.78 million-$283.38 million, compared to the consensus revenue estimate of $180.50 million. When did Valneva IPO? (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO. What is Valneva's stock symbol? Valneva trades on the NASDAQ under the ticker symbol "VALN." How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Valneva's stock price today? One share of VALN stock can currently be purchased for approximately $11.36. How much money does Valneva make? Valneva (NASDAQ:VALN) has a market capitalization of $789.07 million and generates $380.73 million in revenue each year. The company earns $-150,960,000.00 in net income (profit) each year or $0.14 on an earnings per share basis. How many employees does Valneva have? The company employs 719 workers across the globe. How can I contact Valneva? The official website for the company is valneva.com. The company can be reached via phone at 33-2-28-07-37-10 or via email at investors@valneva.com. This page (NASDAQ:VALN) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.